Sun Pharma Joins List Of Indian Pharmas Shadowed By U.S. FDA
This article was originally published in PharmAsia News
Executive Summary
Yet another Indian drug maker, Sun Pharma, has been snared in an FDA enforcement action over quality issues, with an import alert issued over Sun’s Gujarat sites. Although the revenue impact is minimal, Sun saw its stock price fall by 4%.